pentoxifylline has been researched along with Asthma in 6 studies
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bronchial asthma is characterized by persistent airway inflammation and airway wall remodeling." | 5.43 | Pentoxifylline and its active metabolite lisofylline attenuate transforming growth factor β1-induced asthmatic bronchial fibroblast-to-myofibroblast transition. ( Hińcza, K; Kądziołka, D; Koczurkiewicz, P; Madeja, Z; Michalik, M; Pękala, E; Sanak, M; Wnuk, D; Wójcik-Pszczoła, K, 2016) |
| "Tranilast has been used in allergic diseases because of its inhibitory effect on mast cells; it also has an anti-fibrotic effect in several diseases." | 5.35 | Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen. ( Ahn, JH; Kim, CH; Kim, JS; Kim, JW; Kim, SC; Kim, SJ; Kim, YH; Kim, YK; Kwon, SS; Lee, JM; Lee, SH; Lee, SY; Yoon, HK, 2009) |
| "Theophylline is an immunomodulator; however, weak effects and the narrow therapeutic window make it a controversial drug." | 5.30 | Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy? ( Bitter-Suermann, S; Burdon, D; Entzian, P; Ernst, M; Schlaak, M; Zabel, P, 1998) |
| "), treated for ten years only by theophylline for bronchial asthma, we observed spontaneous apoptosis of B lymphocytes (10%)." | 3.69 | [In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications]. ( Baudet, S; Binet, JL; Mentz, F; Merle-Béral, H; Ouaaz, F, 1995) |
| "Bronchial asthma is characterized by persistent airway inflammation and airway wall remodeling." | 1.43 | Pentoxifylline and its active metabolite lisofylline attenuate transforming growth factor β1-induced asthmatic bronchial fibroblast-to-myofibroblast transition. ( Hińcza, K; Kądziołka, D; Koczurkiewicz, P; Madeja, Z; Michalik, M; Pękala, E; Sanak, M; Wnuk, D; Wójcik-Pszczoła, K, 2016) |
| "Tranilast has been used in allergic diseases because of its inhibitory effect on mast cells; it also has an anti-fibrotic effect in several diseases." | 1.35 | Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen. ( Ahn, JH; Kim, CH; Kim, JS; Kim, JW; Kim, SC; Kim, SJ; Kim, YH; Kim, YK; Kwon, SS; Lee, JM; Lee, SH; Lee, SY; Yoon, HK, 2009) |
| "Theophylline is an immunomodulator; however, weak effects and the narrow therapeutic window make it a controversial drug." | 1.30 | Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy? ( Bitter-Suermann, S; Burdon, D; Entzian, P; Ernst, M; Schlaak, M; Zabel, P, 1998) |
| "Platelet aggregation in infectious bronchial asthma patients was examined in vitro and in vivo upon administration of disaggregation agents trental, curantyl, sermion." | 1.28 | [Platelet aggregation inhibitors in the comprehensive treatment of bronchial asthma]. ( Domnikova, NP; Logvinenko, AS; Sidorova, LD, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wójcik-Pszczoła, K | 1 |
| Hińcza, K | 1 |
| Wnuk, D | 1 |
| Kądziołka, D | 1 |
| Koczurkiewicz, P | 1 |
| Sanak, M | 1 |
| Madeja, Z | 1 |
| Pękala, E | 1 |
| Michalik, M | 1 |
| Kim, SJ | 1 |
| Kim, JW | 1 |
| Kim, YH | 1 |
| Lee, SH | 1 |
| Yoon, HK | 1 |
| Kim, CH | 1 |
| Ahn, JH | 1 |
| Lee, JM | 1 |
| Kim, JS | 1 |
| Kim, SC | 1 |
| Lee, SY | 1 |
| Kwon, SS | 1 |
| Kim, YK | 1 |
| Cortijo, J | 1 |
| Bou, J | 1 |
| Beleta, J | 1 |
| Cardelús, I | 1 |
| Llenas, J | 1 |
| Morcillo, E | 1 |
| Gristwood, RW | 1 |
| Binet, JL | 1 |
| Mentz, F | 1 |
| Baudet, S | 1 |
| Ouaaz, F | 1 |
| Merle-Béral, H | 1 |
| Entzian, P | 1 |
| Bitter-Suermann, S | 1 |
| Burdon, D | 1 |
| Ernst, M | 1 |
| Schlaak, M | 1 |
| Zabel, P | 1 |
| Sidorova, LD | 1 |
| Domnikova, NP | 1 |
| Logvinenko, AS | 1 |
6 other studies available for pentoxifylline and Asthma
| Article | Year |
|---|---|
Pentoxifylline and its active metabolite lisofylline attenuate transforming growth factor β1-induced asthmatic bronchial fibroblast-to-myofibroblast transition.
Topics: Anti-Asthmatic Agents; Asthma; Cell Differentiation; Cell Proliferation; Drug Evaluation, Preclinica | 2016 |
Effects of tranilast and pentoxifylline in a mouse model of chronic asthma using house dust mite antigen.
Topics: Animals; Anti-Allergic Agents; Antigens, Dermatophagoides; Asthma; Bronchial Hyperreactivity; Bronch | 2009 |
Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adult; Aged; Animals; Asthma; Bronchodilator Agents; Cyclic Nuc | 1993 |
[In vitro induction of apoptosis in chronic lymphoid leukemia B lymphocytes by theophylline: therapeutic applications].
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Asthma; B-Lymphocytes; Bronchodilator Agents; Ch | 1995 |
Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy?
Topics: Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Blood Cells; Ce | 1998 |
[Platelet aggregation inhibitors in the comprehensive treatment of bronchial asthma].
Topics: Adolescent; Adult; Aged; Asthma; Combined Modality Therapy; Dipyridamole; Female; Humans; Male; Midd | 1991 |